Research
Hormonal
Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.
Start with metformin plus either an SGLT-2 inhibitor or a GLP-1 receptor agonist. This combination is proven to protect your heart and kidneys better than older drugs like sulfonylureas. Focus on lifestyle changes like exercise and healthy eating alongside this medication.
StrongSupportsVERY_HIGH confidence
The initial medical treatment should always be a combination treatment with metformin and a sodium-glucose transporter 2 (SGLT-2) inhibitor or a glucagon-like 1 peptide (GLP-1) receptor agonist.
Why this rating
Based on multiple large-scale cardiovascular outcome trials (EMPA-REG, LEADER) cited in the text.
Source
Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023)
Giacomo Gastaldi et al. · Swiss Medical Weekly · 2023
clinical_guidelineCited 29×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →